BioXcel Therapeutics Announces Database Lock In Serenity At-Home Pivotal Phase 3 Safety Trial For Acute Treatment Of Agitation Associated With Bipolar Disorders Or Schizophrenia
Aug 19 (Reuters) - BioXcel Therapeutics Inc BTAI.O:
BIOXCEL THERAPEUTICS ANNOUNCES DATABASE LOCK IN SERENITY AT-HOME PIVOTAL PHASE 3 SAFETY TRIAL FOR ACUTE TREATMENT OF AGITATION ASSOCIATED WITH BIPOLAR DISORDERS OR SCHIZOPHRENIA
BIOXCEL THERAPEUTICS INC - TOPLINE RESULTS EXPECTED IN AUGUST
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.